Insulin combination at mealtime shows significant reduction in glucose and A1C levels
BRIDGEWATER, N.J. A combination treatment of the insulins Lantus and Apidra, by Sanofi-aventis, at mealtime showed a significant reduction in post meal blood glucose and A1C levels, when using two different dosing methods, found a recent study on diabetes care.
The 24-week study, titled, “Adjust to Target in Type 2 Diabetes: Comparison of a Single Algorithm to Carbohydrate Counting for Adjustment of Mealtime Insulin Glulisine,” compared two algorithms for adjusting mealtime insulin. Apidra and Lantus were adjusted weekly in two groups based on the previous week’s self-monitored blood glucose results.
One group, the “Simplified Algorithm” group, was provided set doses of Apidra to take before each meal. The second group, the “Carbohydrate Counting” group, was provided an insulin-to-carbohydrate ratio to use for each meal and adjusted their Apidra dose based on the amount of carbohydrates consumed. After 24 weeks, the percentage of patients who achieved A1C levels of less than 7 percent—the American Diabetes Association’s recommended target for blood sugar control—while following these two treatment algorithms were 73 and 69 percent, respectively.
Study author Richard Bergenstal, executive director of the International Diabetes Center, Park Nicollet Health Services explained that, “The simplified algorithm investigated in this study allowed patients to start with a fixed dose of Apidra and then effectively adjust to target based on premeal glucose patterns, or to use carbohydrate counting, which involves a mathematical formula that helps patients match the size of their mealtime insulin dose with the amount of carbohydrates they eat. Having two effective options for managing mealtime insulin doses may increase patients’ and clinicians’ willingness to initiate basal-bolus therapy.”
GPhA re-emphasizes need for biogenerics legislation
ARLINGTON, Va. In regards to the meeting of the Joint Economic Committee today on Capitol Hill about the skyrocketing prices of certain prescription drugs, the Generic Pharmaceutical Association released a statement again about the need for biogenerics in this country.
According to GPhA president and chief executive officer Kathleen Jaeger, “Countless patients in need of life-saving biopharmaceutical treatments are struggling to afford their high costs. For patients facing serious conditions such as cancer and heart disease, safe and affordable biogenerics would allow them to improve their lives while reducing their health care costs. With some biopharmaceuticals costing hundreds of thousands of dollars per year, patients must have timely access to life-saving biogeneric medicines.”
The statement also acknowledged a report from the biogeneric company Insmed, which stated that, $236 to $378 billion in savings, could be achieved over 20 years if generic versions of the top 12 categories of biologics with patents that either expired or will soon expire became available to patients.
Jaeger continued, noting that, “these are significant savings that we cannot afford to ignore.”
BMS sees year-on-year earnings increase of nearly $60 million in Q2
NEW YORK The anti-blood clot drug Plavix and the schizophrenia drug Abilify helped boost Bristol-Myers Squibb profits, Bristol announced Thursday.
The company earned $764 million in the second quarter of this year, compared with last year’s $706 million. Bristol expects to save $1.5 billion by 2010, hoping to offset the loss of sales when its patent for Plavix expires in 2012, opening it to generic competition.
Global sales of Plavix jumped to $1.39 billion—17 percent—in Q2, after generic supplies of the medicine that had competed with it for about a year in the United States became exhausted.
Plavix (clopidogrel bisulfate) had sales of $4.755 billion in 2007, according to Bristol financial data.